Trials / Unknown
UnknownNCT04976595
A Study to Monitor Ambulatory Blood Pressure Monitoring in Hypogonadal Men Treated With Nasal Testosterone Gel
A 24-hour Ambulatory Blood Pressure Monitoring Study in Hypogonadal Men Treated With Natesto Nasal Testosterone Gel
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 218 (estimated)
- Sponsor
- Acerus Pharmaceuticals Corporation · Industry
- Sex
- Male
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the change in 24-hour ambulatory blood pressure monitoring (ABPM) between baseline (Day 0) and Day 120 following 4 months of testosterone therapy with Natesto.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Natesto | Nasal gel containing testosterone 11 mg/dose (5.5 mg/nostril) three times daily. |
Timeline
- Start date
- 2021-07-01
- Primary completion
- 2022-12-01
- Completion
- 2022-12-01
- First posted
- 2021-07-26
- Last updated
- 2022-07-06
Locations
30 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04976595. Inclusion in this directory is not an endorsement.